PureTech Health (PRTC) Cash & Equivalents (2019 - 2024)
PureTech Health (PRTC) has disclosed Cash & Equivalents for 3 consecutive years, with $149.9 million as the latest value for Q4 2022.
- On a quarterly basis, Cash & Equivalents fell 67.82% to $149.9 million in Q4 2022 year-over-year; TTM through Dec 2022 was $149.9 million, a 67.82% decrease, with the full-year FY2022 number at $149.9 million, down 67.82% from a year prior.
- Cash & Equivalents was $149.9 million for Q4 2022 at PureTech Health, down from $465.7 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $465.7 million in Q4 2021 to a low of $149.9 million in Q4 2022.
- A 3-year average of $339.8 million and a median of $403.9 million in 2020 define the central range for Cash & Equivalents.
- Peak YoY movement for Cash & Equivalents: increased 15.31% in 2021, then crashed 67.82% in 2022.
- PureTech Health's Cash & Equivalents stood at $403.9 million in 2020, then increased by 15.31% to $465.7 million in 2021, then plummeted by 67.82% to $149.9 million in 2022.
- Per Business Quant, the three most recent readings for PRTC's Cash & Equivalents are $149.9 million (Q4 2022), $465.7 million (Q4 2021), and $403.9 million (Q4 2020).